Bruce Booth
@LifeSciVC
Early stage biotech VC. Recovering scientist.
Opinions expressed are solely my own and do not express the views or opinions of Atlas Venture.
ID:229246832
http://www.atlasventure.com 21-12-2010 22:35:43
11,9K Tweets
49,7K Followers
732 Following
'Deconstructing the Diligence Process: An Approach to Vetting New Product Theses'
Atlas' Aimee Raleigh opines in a fantastic new blog covering:
- Target Validation
- Directionality and Druggability
- Pharmacology
- Path to PoC
- Product Opportunity
lifescivc.com/2024/04/decons…
First disclosure of our STAT3 degrader KT-333 and its biochemical mechanism of action. This presentation highlights how we select the right E3 for each target and our sophisticated ternary complex characterization including cryo EM studies. Great work from the Kymera Therapeutics team!
We are delighted to share the #Science2Startup class of 2024!
This year’s 8 scientific presenters were selected by an advisory group of experienced #biotech investors to present their #startup ideas on April 10th at the Broad Institute.
Learn more: science2startup.com
Fun and thought-provoking list of Pharma/R&D questions (and some data) to skim through...
Thx Frank S. David for sharing.
Devastated. A supreme scientific mentor, R&D leader and a true giant of our industry. Learnt so much over the past 29 years at his feet on ‘doing the killer experiment’ ‘show me the data’ ’the world belongs to finishers’. Bruce Booth John Maraganore 🇺🇦🇮🇱
. Atlas Venture's Bruce Booth sees biotech's belt-tightening starting to yield more favorable financing environment, but there's still pain to come. + how new modalities will play out. Watch Bruce Booth in conversation BioCentury's Simone Fishburn youtu.be/z5R4SUI5kns